Work

O47 Chez des patients diabétiques de type 2, l’antagoniste du récepteur du glucagon LY2409021 diminue significativement l’HbA1c et est bien toléré après 12 semaines de traitement

Year: 2013

Type: conference-abstract

Source: Diabetes & Metabolism

DOI: 10.1016/s1262-3636(13)71659-8

Authors: C. Bonnard, C. Kazda, P. Garhyan, R.P. Kelly, C. Shi, C. Ngee Lim, H. Fu, M. Deeg

Institutions: Eli Lilly (United States), Eli Lilly (Singapore)

Language: French

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2069640261

Cites:

Cited by:

Related to: 10